|
|
Сonditions and diseases
AIDS/HIV ALS Alzheimer's Disease Anemia Anti-Aging Treatment Arterial Hypertension Autism Cancer Diabetes Treatment Eye Diseases Idiopathic Encephalopathy Ischemic Heart Disease Liver Diseases MD Treatment Multiple Sclerosis Treatment Parkinson Treatment Rheumatoid Arthritis SMA Ulcerative Colitis. Crohn’s Disease
News about stem cells
Stem cell treatment protects bone marrow from damaging chemotherapy effects in cancer patients
12 May
Stem cell therapy can protect cancer patients from damaging side-effects of chemotherapy, a new trial in the US suggests.
12 May
Stem cell therapy can protect cancer patients from damaging side-effects of chemotherapy, a new trial in the US suggests.
New Approach to Treating Muscular Dystrophy With Stem Cells
05 May
Scientists from the Lillehei Heart Institute (University of Minnesota) have developed a new efficient process of making muscle cells from human stem cells and for the first time ever effectively treated with these cells muscular dystrophy in a mice model.
05 May
Scientists from the Lillehei Heart Institute (University of Minnesota) have developed a new efficient process of making muscle cells from human stem cells and for the first time ever effectively treated with these cells muscular dystrophy in a mice model.
A New Brain Stem Cell Discovered
29 April
Adult brain contains stem cells, and Researchers at Lund University (Switzerland) found a new type of these cells.
All news
29 April
Adult brain contains stem cells, and Researchers at Lund University (Switzerland) found a new type of these cells.
Treatment of DMD in patient R. Medical case report No.3
We had honor to accept at EmCell clinic Mr. R. attended by his parents.
The patient complains of the walking disorders, muscle weakness, inability to walk up and down stairs, to get up from the floor without help.
Examination by the neurologist
According to the parents, for half a year the condition of the boy has been satisfactory. Starting from March, some decrease in the quality of movement activity was observed. Within half a year the boy has gained 11 pounds (5 kg) in weight and 2–3 inches (7.5 cm) in height. The walking had improved - the expression of lordosis has diminished, he walks stepping with the full foot, can run. The strength in arms and legs has increased, hypotrophy of shoulder girdle muscles, and especially in pelvic girdle, has diminished. Arm reflexes D=S, knee - D=S, heel S=D; plantar reflexes are reported periodically. Gets up from the bed by himself. Sight is fixed, movements of eye apples are to a full range, convergence is good. The boy is in good spirits, attentive, does well in his studies. So, there is obvious positive progress in physical activity as well as growth and weight gain.
Diagnosis: Duchenne Muscular Dystrophy.
Lab tests (blood count, chemistry, routine urine test) were normal.
Recommendations: continue cell therapy.
Mr. R. received a course of cell therapy:
1st day of treatment. Transplantation of sample 3038I212 i.v. dropwise, 0.9 ml. Implantation of the sample 3038IM212 s/c in frontal abdomen, in two depots, 0.7 ml each. Implantation of sample 3038IE212, s/c in buttocks, in two depots, 1.0 ml each.
2nd day of treatment. Transplantation of sample 3038I212 i.v. dropwise, 0.9 ml. Implantation of sample 3038IM212 s/c in frontal abdomen, in two depots, 0,7 ml each. Implantation of sample 3038IE212, s/c in buttocks, in two depots, 0.8 ml each.
4th day of treatment. Transplantation of sample 3038A498 i.v. dropwise, 2.0 ml. Implantation of sample 3038AM498, s/c in frontal abdomen, in two depots, 1,1 ml each. Implantation of sample 3038IE406, s/c in buttocks, in two depots, 0.9 ml each.
5th day of treatment. Transplantation of sample 3038A498 i.v. dropwise, 1.0 ml. Implantation of sample 3038AE498, s/c in frontal abdomen, in two depots, 0.9 ml each.
7th day of treatment. Implantation of sample 3038AE498, s/c in frontal abdomen, in two depots, 1.2 ml each.
The cell suspension samples 30381212, 3038IM212, 3038IE212, 3038A498, 3038AM498, 3038IE406, and 3038AE498 are certified as follows:
Results of the treatment
During the course of treatment were observed the following positive changes: increase of the range of activity, good spirits.
Mr. R. is recommended:
1. Follow-up by the neurologist in the USA.
2. Diet rich in proteins (veal, fish, mushrooms, etc.).
3. Regular training in movement of legs and arms. Monthly measurements of weight and height.
4. Avoid infections.
5. Repeated course of cell therapy in 6–8 months. The exact timing of the visit is to be arranged in accordance with the changes of the patient's condition.
The patient complains of the walking disorders, muscle weakness, inability to walk up and down stairs, to get up from the floor without help.
Examination by the neurologist
According to the parents, for half a year the condition of the boy has been satisfactory. Starting from March, some decrease in the quality of movement activity was observed. Within half a year the boy has gained 11 pounds (5 kg) in weight and 2–3 inches (7.5 cm) in height. The walking had improved - the expression of lordosis has diminished, he walks stepping with the full foot, can run. The strength in arms and legs has increased, hypotrophy of shoulder girdle muscles, and especially in pelvic girdle, has diminished. Arm reflexes D=S, knee - D=S, heel S=D; plantar reflexes are reported periodically. Gets up from the bed by himself. Sight is fixed, movements of eye apples are to a full range, convergence is good. The boy is in good spirits, attentive, does well in his studies. So, there is obvious positive progress in physical activity as well as growth and weight gain.
Diagnosis: Duchenne Muscular Dystrophy.
Lab tests (blood count, chemistry, routine urine test) were normal.
Recommendations: continue cell therapy.
Mr. R. received a course of cell therapy:
1st day of treatment. Transplantation of sample 3038I212 i.v. dropwise, 0.9 ml. Implantation of the sample 3038IM212 s/c in frontal abdomen, in two depots, 0.7 ml each. Implantation of sample 3038IE212, s/c in buttocks, in two depots, 1.0 ml each.
2nd day of treatment. Transplantation of sample 3038I212 i.v. dropwise, 0.9 ml. Implantation of sample 3038IM212 s/c in frontal abdomen, in two depots, 0,7 ml each. Implantation of sample 3038IE212, s/c in buttocks, in two depots, 0.8 ml each.
4th day of treatment. Transplantation of sample 3038A498 i.v. dropwise, 2.0 ml. Implantation of sample 3038AM498, s/c in frontal abdomen, in two depots, 1,1 ml each. Implantation of sample 3038IE406, s/c in buttocks, in two depots, 0.9 ml each.
5th day of treatment. Transplantation of sample 3038A498 i.v. dropwise, 1.0 ml. Implantation of sample 3038AE498, s/c in frontal abdomen, in two depots, 0.9 ml each.
7th day of treatment. Implantation of sample 3038AE498, s/c in frontal abdomen, in two depots, 1.2 ml each.
The cell suspension samples 30381212, 3038IM212, 3038IE212, 3038A498, 3038AM498, 3038IE406, and 3038AE498 are certified as follows:
| Bacterial sterility test | Negative |
| Prenatal Diagnostics | |
| Test with cardiolipid antigen | Negative |
| Ami - HIV1/HIV2 | Negative |
| HBsAg | Negative |
| Embryonic Diagnostics | |
| Enzygnost Ami - HIV1/HIV2 | Negative |
| HBsAg monoclonal | Negative |
| Anti - HBc monoclonal | Negative |
| Anti - CMV/IgG+IgM | Negative |
| Anti - Rubella Virus/IgG | Negative |
| Varicella/Zoster | Negative |
| Toxoplasmosis/IgG | Negative |
Results of the treatment
During the course of treatment were observed the following positive changes: increase of the range of activity, good spirits.
Mr. R. is recommended:
1. Follow-up by the neurologist in the USA.
2. Diet rich in proteins (veal, fish, mushrooms, etc.).
3. Regular training in movement of legs and arms. Monthly measurements of weight and height.
4. Avoid infections.
5. Repeated course of cell therapy in 6–8 months. The exact timing of the visit is to be arranged in accordance with the changes of the patient's condition.